We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

49 hedge funds and large institutions have $206M invested in VanEck Pharmaceutical ETF in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

59% more capital invested

Capital invested by funds: $129M → $206M (+$76.6M)

48% more call options, than puts

Call options by funds: $2.61M | Put options by funds: $1.76M

14% more funds holding

Funds holding: 43 → 49 (+6)

7.66% more ownership

Funds ownership: 94.95% → 102.62% (+7.7%)

38% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 13

Holders
49
Holders Change
+6
Holders Change %
+13.95%
% of All Funds
0.97%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
8
Reduced
13
Closed
5
Calls
$2.61M
Puts
$1.76M
Net Calls
+$852K
Net Calls Change
+$835K

Top Buyers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
+$68.3M
2
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$36.4M
3
WWM
Western Wealth Management
Colorado
+$4.45M
4
CI
Clal Insurance
Israel
+$861K
5
TRCT
Tower Research Capital (TRC)
New York
+$745K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$48.3M
2
Wells Fargo
Wells Fargo
California
-$9.04M
3
JP Morgan Chase
JP Morgan Chase
New York
-$5.74M
4
Goldman Sachs
Goldman Sachs
New York
-$1.21M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
NSIM
26
North Star Investment Management
Illinois
$81K -$75K -1,244 -50%
GT
27
Glenmede Trust
Pennsylvania
$64K – – –
TCM
28
Tradewinds Capital Management
Washington
$64K – – –
AG
29
Advisor Group
Arizona
$50K – – –
ASN
30
Advisory Services Network
Georgia
$43K -$6.39K -106 -14%
IA
31
IFP Advisors
Florida
$40K +$37.4K +620 New
FDCDDQ
32
Federation des caisses Desjardins du Quebec
Quebec, Canada
$38.5K – – –
LWM
33
Liberty Wealth Management
California
$38K +$1.57K +26 +5%
CFGS
34
Concourse Financial Group Securities
Alabama
$32K – – –
Citigroup
35
Citigroup
New York
$22K – – –
PNC Financial Services Group
36
PNC Financial Services Group
Pennsylvania
$22K +$21.1K +350 New
MIM
37
Macroview Investment Management
Maryland
$19K – – –
EIP
38
Ellis Investment Partners
Pennsylvania
$16K +$60 +1 +0.4%
JCM
39
Jacobi Capital Management
Pennsylvania
$13K – – –
Fidelity Investments
40
Fidelity Investments
Massachusetts
$13K +$60 +1 +0.5%
HCM
41
Highlander Capital Management
New Jersey
$9K – – –
Barclays
42
Barclays
United Kingdom
$6K – – –
SFS
43
Sowell Financial Services
Arkansas
$6K – – –
William Blair & Company
44
William Blair & Company
Illinois
$6K – – –
FANJ
45
Financial Architects (New Jersey)
New Jersey
$5K – – –
NL
46
NVWM LLC
Pennsylvania
$4K -$1.15K -19 -22%
AIM
47
Anchor Investment Management
South Carolina
$3.72K – – –
WCG
48
Weaver Consulting Group
California
$1K – – –
LS
49
Leelyn Smith
Illinois
$16 +$14.8K +245 New
JP Morgan Chase
50
JP Morgan Chase
New York
– -$5.74M -100,880 Closed
1
2
3

PPH Hedge Fund Activity: Q4 2019 in Review

49 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2019, worth a combined $206M — up 59% from $129M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new PPH positions and 5 closed out — a net gain of 6 holders — while 8 added to existing stakes and 13 trimmed.

The largest buyer was Credit Suisse, opening a new position worth an estimated $68.3M. The largest seller was Bank of America, cutting an estimated $48.3M.

  • 49 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2019, up from 43 in Q3 2019.
  • Funds reported $206M of VanEck Pharmaceutical ETF stock for Q4 2019, up 59% quarter-over-quarter.
  • 11 funds opened new VanEck Pharmaceutical ETF positions in Q4 2019 and 5 closed out, a net change of +6 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q4 2019 was Credit Suisse, an estimated $68.3M added.
  • The largest VanEck Pharmaceutical ETF seller in Q4 2019 was Bank of America, an estimated $48.3M sold.

Based on aggregated 13F filings for Q4 2019.